Clinical Trial Update: Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme [Phase 1, Phase 2]

View source ↗

Summary

This update reports the results of a Phase 1/2 study evaluating SL-701, a glioma-associated antigen vaccine, in patients with recurrent glioblastoma multiforme.…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• SL-701

Snippet

Sponsor: Stemline Therapeutics, Inc. | Conditions: Adult Brain Glioblastoma, Glioblastoma Multiforme | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2023-12-06